CRISPR Therapeutics CEO sells 4,098 shares for taxes

Q: How many CRSP restricted stock units vested for Samarth Kulkarni in October 2026?

8,333 restricted stock units converted into 8,333 Common Shares on October 13, 2026. The award was granted on October 13, 2023, with respect to 25,000 Common Shares, with one third vesting on each of October 13, 2024, October 13, 2025, and October 13, 2026.

The sale was required under the company's RSU Settlement Policy to fund tax withholding, rather than a discretionary trade.

Filing Impact

(High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CRISPR Therapeutics AG (CRSP) Chief Executive Officer Samarth Kulkarni received 8,333 Common Shares on October 13, 2026, when 8,333 restricted stock units vested. On October 14, 2026, he sold 4,098 Common Shares at $49.26 per share. The sale was required under the company's RSU Settlement Policy to fund tax withholding and was not a discretionary trade.

Insights

Analyzing...

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Kulkarni Samarth

Role Chief Executive Officer

Sold 4,098 shs ($202K)

Approx. gross sale proceeds $202K

Type	Security	Shares	Price	Value
Sale	Common Shares ^F2	4,098	$49.26	$202K
Exercise	Restricted Stock Units ^{F1, F3}	8,333	--	--
Exercise	Common Shares ^F1	8,333	--	--

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Shares — 259,736 shares (Direct)

Footnotes (3)

F1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3. This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.

Key Figures

Common Shares sold: 4,098 shares Sale price: $49.26 per share Restricted stock units vested: 8,333 units +1 more

4 metrics

Common Shares sold 4,098 shares October 14, 2026; required sale to fund tax withholding

Sale price $49.26 per share Common Shares sold on October 14, 2026

Restricted stock units vested 8,333 units October 13, 2026

Common Shares acquired 8,333 shares Received upon conversion of restricted stock units on October 13, 2026

Key Terms

restricted stock unit, RSU Settlement Policy, tax withholding obligation

3 terms

restricted stock unit financial

"Each restricted stock unit represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU Settlement Policy financial

"mandated by the Company's RSU Settlement Policy"

tax withholding obligation financial

"to fund the tax withholding obligation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CRSP shares did CEO Samarth Kulkarni sell, and at what price?

Samarth Kulkarni, CRISPR Therapeutics AG's Chief Executive Officer, sold 4,098 Common Shares at $49.26 per share on October 14, 2026. The sale was required under the company's RSU Settlement Policy to fund tax withholding for restricted stock unit vesting and was not discretionary. No Rule 10b5-1 plan is reported.

How many CRSP restricted stock units vested for Samarth Kulkarni in October 2026?

8,333 restricted stock units converted into 8,333 Common Shares on October 13, 2026. The award was granted on October 13, 2023, with respect to 25,000 Common Shares, with one third vesting on each of October 13, 2024, October 13, 2025, and October 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/15/2026 - 05:35 PM EDT Accepted by SEC EDGAR 10/15/2026 - 05:35 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Samarth

(Last)

(First)

(Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON

MASSACHUSETTS

02127

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	10/13/2026		M		8,333	A	⁽¹⁾	263,834	D
Common Shares	10/14/2026		S		4,098⁽²⁾	D	$49.26	259,736	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	10/13/2026		M			8,333	⁽³⁾	⁽³⁾	Common Shares	8,333	⁽¹⁾	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

2. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

3. This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	10/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR